Tirzepatide is the same drug as Mounjaro. Tirzepatide is the active ingredient, and Mounjaro is the brand name given to it by its manufacturer, Eli Lilly. Think of it the way ibuprofen is the drug inside Advil. The distinction matters because tirzepatide is also sold under a second brand name, Zepbound, for a different medical purpose.
One Drug, Two Brand Names
Mounjaro and Zepbound are molecularly identical. They contain the same active ingredient (tirzepatide), are made by the same company, and work exactly the same way in your body. The only real difference is what the FDA approved each one to treat. Mounjaro is approved for improving blood sugar control in adults with type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) who also have at least one weight-related condition like high blood pressure or high cholesterol.
Because they are the exact same medication, Mounjaro and Zepbound should never be used together. Combining them would simply mean double-dosing tirzepatide.
How Tirzepatide Works
Tirzepatide activates two gut hormone receptors at once, which is what sets it apart from older medications in the same class. One of those hormones helps your body release insulin more effectively after eating. The other plays a role in how your body processes fat and regulates appetite. Most similar drugs only target one of these pathways. Tirzepatide leans more heavily on the first receptor while still engaging the second, creating a combined effect that drives both blood sugar reduction and significant weight loss.
This dual action is why tirzepatide produced such strong results in clinical trials for both diabetes and obesity, and why it ended up with two separate brand approvals.
Blood Sugar and Weight Loss Results
Tirzepatide was tested across a large series of clinical trials called SURPASS, which enrolled people with type 2 diabetes. The results were consistently strong across different comparisons. Up to 92% of participants reached a blood sugar level (measured by A1C) below 7%, which is the target most guidelines recommend for people with diabetes. Even more striking, up to 62% of participants brought their A1C below 5.7%, a level typically seen in people without diabetes.
In head-to-head testing against semaglutide (the active ingredient in Ozempic and Wegovy), all three tirzepatide doses produced greater reductions in both A1C and body weight. It also outperformed insulin in trials, delivering better blood sugar control with the added benefit of weight loss rather than weight gain.
How You Take It
Tirzepatide is a once-weekly injection given under the skin of your stomach, thigh, or the back of your upper arm. You pick one day of the week and stick with it. Timing doesn’t matter, and you don’t need to coordinate it with meals.
Everyone starts at 2.5 mg per week, which is considered an introductory dose to let your body adjust rather than a treatment dose. After four weeks, the dose increases to 5 mg. From there, your doctor can raise it in 2.5 mg steps every four weeks or longer, depending on how you respond. The maximum dose is 15 mg per week. This gradual ramp-up is designed to reduce the digestive side effects that are common with this class of medication, including nausea, diarrhea, and reduced appetite.
Is Generic Tirzepatide Available?
No. The FDA has not approved a generic version of tirzepatide, and it won’t be available for some time. Eli Lilly holds multiple patents on the drug, with expiration dates stretching from 2036 to 2041. A period of regulatory exclusivity for the new chemical entity runs through May 2027, and a separate exclusivity window for the weight management approval extends to December 2028. Even after those exclusivity periods end, the patents themselves would block generic competitors for years.
Compounded versions of tirzepatide have been available through some pharmacies during periods of drug shortage, but these are not FDA-approved generics. They are pharmacy-prepared copies made under different regulatory rules, and their availability can change as the supply situation shifts.
Why the Naming Confusion Exists
The two-name system trips people up for good reason. Doctors, pharmacists, and insurance companies may refer to the drug differently depending on context. A prescription might say “Mounjaro” or “tirzepatide” and mean the same thing. Online searches for tirzepatide pull up results about Mounjaro, Zepbound, and compounded versions all at once. If your doctor mentions tirzepatide and your pharmacy label says Mounjaro, you’re getting what was prescribed. The same applies if you see Zepbound on a label for a weight management prescription. All three names point to the same molecule.